Heptares Therapeutics Limited
Drug Discovery Company
Website
www.heptares.com/
Contact Name
Dr. Malcolm Weir
Company Position
Chief Executive Officer
Contact Email
malcolm.weir@heptares.com
Contact Address
BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX
UK
Contact Phone
+44 1707 356100
Latest News
12th October 2009
Heptares has entered into an option agreement with the Novartis Option Fund, which includes upfront and potential milestone payments totaling up to $200 million plus royalties.
Read this article
More News
5th October 2009
Heptares Therapeutics Ltd has appointed Dr Barry Kenny as its Chief Business Officer to focus on business development and strategic alliances based on the Company’s unique StaR™ technology
Read this article
24th February 2009
Heptares Therapeutics Ltd (HTL), the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), has announced that it has raised £21 million (US$30million) in a successful Series A.
Read this article
7th August 2007
Heptares Therapeutics Limited is a new drug discovery company whose aim is to apply structural knowledge of G-protein coupled receptors to the design and development of its own drug molecules.
Read this article
Heptares Therapeutics Ltd (HTL) is a drug discovery company whose aim is to apply structural knowledge of G-protein coupled receptors (GPCRs) to the design and development of its own drug molecules.
It will operate principally in the Central Nervous System and metabolic disease areas. These diseases affect many millions of people worldwide and Heptares will fulfill an important role in addressing unmet medical need in these therapeutic areas. GPCRs are the single most important family of drug targets in the human genome, yet there are many clinically relevant targets that are progressing slowly and for which structural information, were it available, would be likely to make a major difference.
HTL is a spin-out from the MRC Laboratory of Molecular Biology, Cambridge, based on the pioneering work of the founding scientists Richard Henderson and Chris Tate and of a wider group of MRC scientists, including Gebhard Schertler, and Ed Hulme of the National Institute of Medical Research, Mill Hill, London. HTL is managed by Malcolm Weir (Chief Executive Officer) and Fiona Marshall (Chief Scientific Officer), with John Berriman as Chairman, and is based at Welwyn BioPark.
